×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu

Tag: MEA

Shares / Technology

Seek Delays Dividend, McGrath Drops Guidance

April 7, 2020April 6, 2020 - by Glenn Dyer

Seek was another company yesterday to withdraw its earnings guidance and postpone the payment of dividends because of the COVID-19 pandemic.

Read More
Property / Shares

McGrath Confirms Weak Result, Soft Outlook

February 19, 2019February 18, 2019 - by Glenn Dyer

A not unexpected weak result from Sydney real estate agency, McGrath for the six months to the end of December, and a not unexpected weak forecast of ongoing tough property market conditions in the short term, thanks to the uncertainty caused by the NSW and federal elections.

Read More
Property / Shares

Softer Property Market Sinks McGrath

October 24, 2018October 23, 2018 - by Glenn Dyer

A weak interim profit lies ahead for struggling real estate agency McGrath which yesterday reported a small loss for the first quarter of 2018-19 and all but admitted the company will not make a profit for the year to June 30 on an after-tax basis.

Read More
Shares

New Writedown Provides More Misery For McGrath

August 1, 2018 - by Glenn Dyer

More bad news for the listed real estate agency McGrath yesterday with investors warned to expect a bottom line loss of more than $50 million for the year to June 30.

Read More
Shares

Embattled McGrath Provides Another Profit Warning

March 13, 2018September 5, 2018 - by Glenn Dyer

More revenue and profit woes for embattled listed real estate agency McGrath Ltd as it reveals its second or third earnings downgrade of the year so far.

Read More
Shares

Embattled McGrath Unveils New Directors

February 20, 2018September 5, 2018 - by Glenn Dyer

Shares in battling real estate agency group, McGrath rose nearly 4.9%on Monday, ending at 43 cents after a new chairman and director were announced in time to stave off the company being in breach of ASX listing rules for minimum board requirements.

Read More
Shares

Headline Grabbing McGrath Posts Big Loss

February 16, 2018September 5, 2018 - by Glenn Dyer

For such a small, insignificant company, real estate group McGrath continues to generate a lot of publicity – all of it bad. Yesterday we saw a big loss, big fall in revenue, a results briefing cancelled and then trading in the shares halted at the company’s request, which is quite a mouthful for just one day.

Read More
Shares

Sellers Savage McGrath On New Downgrade

November 7, 2017 - by Glenn Dyer

Shares in real estate agency group McGrath closed badly battered yesterday after the Sydney-based real estate company cut its earnings guidance and promised an intense round of cost cutting.

Read More
Shares

‘Unprecedented’ Low Listings Hit McGrath

February 24, 2017 - by Glenn Dyer

It wasn’t the biggest result, nor the worst, but it did contain a warning for many other companies in and around the property and home lending businesses.

Read More
Shares

McGrath Set To Miss Earnings

January 24, 2017 - by Glenn Dyer

Shares in one of the country’s largest real estate agents, McGrath (MEA), dived yesterday after it warned of a weak June half year.

Read More
Roger Montgomery

McGrath’s Problems With Its Partners

April 20, 2016 - by Stuart Jackson

McGrath Estate Agents (ASX: MEA) share price fell over 30 per cent on the back of an announcement that its profits will fall short of the prospectus forecasts in FY16.

Read More
Shares

McGrath Passed In

April 19, 2016 - by Glenn Dyer

Struggling listed real estate agency group, McGrath Limited (MEA) has been forced to slash its dividend target from 4.5 cents a share to 3 to 3.5 cents a share after it was forced to cut its sales estimates for the 2016 financial year.

Read More
  • Evening Report: ASX 200 hits 11-month highs
  • Lunch Report: Technology, energy and industrial stocks lead ASX higher
  • Australia…One Hour In…ASX up 40 points
  • Bell Potter LIC Weekly: WAM, Magellan
  • RIO – UBS rates the stock as Neutral
  • HUB – Credit Suisse rates the stock as Upgrade to Outperform
  • BIN – Morgans rates the stock as Hold
  • HMC – Morgans rates the stock as Add

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Financial Services Guide | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Truck.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Tree.

DOWNLOAD RESEARCH REPORT

A Laser-Like Focus on Adding Value

Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Cup.